GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Stock Based Compensation

Regnum (Regnum) Stock Based Compensation : $0.00 Mil (TTM As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Regnum Stock Based Compensation?

Regnum's Stock Based Compensation for the three months ended in Mar. 2023 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.


Regnum Stock Based Compensation Historical Data

The historical data trend for Regnum's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Stock Based Compensation Chart

Regnum Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial - - - - -

Regnum Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regnum Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


Regnum Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Regnum's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Regnum (Regnum) Business Description

Traded in Other Exchanges
N/A
Address
600 Third Avenue, 19th Floor, New York, NY, USA, 10016
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines